II. Prospects for development of new antimicrobials for clinical control of tuberculosis: 2. Current status and perspectives on the development of rifamycin derivative antibiotics

Kekkaku

Volumn 74, Issue 1, 1999, Pages 53-61

  Hidaka, Takayoshi ^a  

^a KANEKA CORPORATION   (Japan)

Author keywords

KRM 1648; Rifabutin; Rifampicin; Rifamycin derivatives; Rifapentine; Tuberculosis

Indexed keywords

3 [(1 DIETHYLAMINOETHYLIDENE)AZINOMETHYL]RIFAMYCIN SV; 3 [4 (2,4,6 TRIMETHYLBENZYL) 1 PIPERAZINYL]RIFAMYCIN SV; CGP 29861; ISONIAZID; PROTEINASE INHIBITOR; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; RIFAXIMIN; RIFAMYCIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; CLINICAL TRIAL; CONFERENCE PAPER; DOG; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; TISSUE DISTRIBUTION; TUBERCULOSIS; ANTIBIOTIC RESISTANCE; DRUG DESIGN; DRUG EFFECT; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTIBIOTICS, ANTITUBERCULAR; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RIFAMYCINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0032603534     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Tuberculosis, trends and opportunities. In Scrip Reports, Bloomfield G, ed. PJB Publication Ltd, 1995 : 85-101.
2. Health News Daily : June 24, 1998 ; 10 : 121.
3. Traxler P, Vischer WA and Zak O : New rifamycins. Drugs of the future. 1988 ; 13 : 845-856.
4. Birmingham AT, Coleman AJ, Orme MLE, et al. : Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin). Br J Clin Pharmacol. 1978 ; 6 : 455-456p.
5. Arioli V, Berti M, Carniti G, et al. : Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J Antibiot. 1981 ; 34 : 1026-1032.
6. Della-Bruna C, Schioppacassi G, Ungheri, et al. : LM427, a new spiro - piperidylrifamycin : in vitro and in vivo studies. J Antibiot. 1983 ; 36 : 1502-1504.
7. Heifets LB, Iseman MD, Lindholm-Levy, et al. : Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob Agents Chemother. 1985 ; 28 : 570-574.
8. Gillis JC, Brogden RN. : Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potentials in conditions mediated by gastrointestinal bacteria. Drugs. 1995 ; 49 : 467-484.
9. Descombe JJ, Dubourg D, Picard M, et al. : Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharm Res. 1994 ; XIV : 51-56.
10. Yamane T, Hashizume T, Yamashita, et al. : Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull. 1993 ; 41 : 148-155.
11. Saito H, Tomioka H, Sato K, et al. : In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother. 1991 ; 35 : 542-547.
12. Luna-Herrera J, Reddy MV, Gangadharam PR. : In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrob Agents Chemother. 1995 ; 39 : 440-444.
13. Hirata T, Saito H, Tomioka H, et al. : In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1995 ; 39 : 2295-2303
14. Moghazeh SL, Pan X, Arain T, et al. : Comparative antimycobacterial activities of rifampin, rifapentine, and KRM - 1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother. 1996 ; 40 : 2655-2657.
15. Tomioka H, Saito H, Sato K, et al. : Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother. 1992 ; 36 : 387-393.
16. Inderlied CB, Barbara-Burnham L, Wu M, et al. : Activities of the benzoxazinorifamycin KRM-1648 and ethanbutol against Mycobacterium avium complex in vitro and in macrophage. Antimicrob. Agents Chemother. 1994 ; 38 : 1838-1843.
17. Bermudez LE, Kolonoski P, Young LS, et al. : Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrob. Agents Chemother. 1994 ; 38 : 1844-1848.
18. Klemens SP, Grossi MA, Cynamon MH. : Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 1994 ; 38 : 2245-2248.
19. Klemens SP and Cynamon MH. : Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 1996 ; 40 : 298-301.
20. Yamamoto T, Amitani R, Suzuki K, et al. : Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or ciarithromycin against Mycobacterium intracellulare infection in beige mice. Antimicrob. Agents Chemother. 1996 ; 40 : 429-432.
21. Yamamoto T, Amitani R, Suzuki K, et al. : In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1996 ; 40 : 426-428.
22. Mor N, Simon B, Heifets L: Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrob. Agents Chemother. 1996 ; 40 : 1482-1485.
23. Sato K, Akai T and Tomioka H : Antimicrobial activities of benzoxazinorifamycin KRM-1648, ciarithromycin and levofloxacin against intracellular Mycobacterium avium complex phargocysed by murine peitoneal macropharges. J Antimicrob Chemother. 1998 ; 41 : 77-83.
24. Hosoe K, Mae T, Konishi E, et al. : Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob Agents Chemother. 1996 , 40 : 2749-2755.
25. Hosoe K, Mae T, Yamashita K, et al. : Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog. Xenobiotica. 1996 ; 26 : 321-332.
26. Mae T, Hosoe K, Fujii K, et al. : In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. Xenobiotica. 1996 ; 26 : 793-802.
27. Iatsimirdkaia E, Tulebaev S, Storozhuk E, et al. : Metabolism of rifabutin in human enterocyte and liver microsomes : Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther. 1997 ; 61 : 554-562.
28. Jamis-Dow CA, Katki AG, Collins JM, et al. : Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica. 1997 ; 27 : 1015-1024.
29. Li AP, Reith MK, Rasmussen A, et al. : Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics : Evaluation of rifampin, rifapentine and rifabutin. Chemico-Biol Interact. 1997 ; 107 : 17-30.
30. Strolin Benedetti M, Dostert P : Induction and autoinduction properties of rifamycin derivatives : A review of animal and human studies. Environ Health Perspect. 1994 ; 102 (Suppl 9) : 101-105.
31. Horn JR, Hansten PD : Drug interactions with antibacterial agents. J Family Practice. 1995 ; 41 : 81-90.
32. Gillum JG, Israel DS, Polk RE : Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet. 1993 ; 25 : 450-482.
33. Grange JM, Winstanley PA, Davies PDO : Clinically significant drug interactions with antituberculosis agents. Drug Safety. 1994 ; 11 : 242-251.
34. Strayhorn VA, Baciewicz AM, Self TH : Update on rifampin drug interactions, III. Arch Intern Med. 1997 ; 157 : 2453-2458.
35. Antituberculosis agents. In : AHFS Drug Information 97, McEvoy, GK ed. The American of Health-system Pharmacists. 1997 ; 408 -439.
36. Clinical update : Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep, 1996 ; 45 : 921-925.
37. Mae T, Hosoe K, Yamamoto T, et al. : Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica. 1998 ; 28 : 759-766.